Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question
CyPath Lung is gaining clinical traction. The harder test is whether bioAffinity can scale adoption before cash pressure tightens.
Artera’s EU breakthrough in AI cancer testing opens a bigger battle over workflow, trust, and scale
Artera has won CE marking for its AI prostate and breast cancer assays. Read what this means for oncology diagnostics, adoption, and global expansion.